Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm, Residual × Lenalidomide × 30 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 39 Lymphoma, Follicular 12 Lymphoma, Large B-Cell, Diffuse 9 Recurrence 5 Lymphoma, Non-Hodgkin 5 Lymphoma, B-Cell, Marginal Zone 5 Lymphoma 5 Neoplasms 4 Lymphoma, Mantle-Cell 4 Leukemia, Lymphocytic, Chronic, B-Cell 4 Neoplasms, Plasma Cell 3 Smoldering Multiple Myeloma 2 Myelodysplastic Syndromes 2 Lymphoma, B-Cell 2 Leukemia, Myelomonocytic, Chronic 2 Hodgkin Disease 2 Waldenstrom Macroglobulinemia 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Paraproteinemias 1 Neuroblastoma 1 Neoplasm, Residual 1 Lymphoproliferative Disorders 1 Lymphoma, Large-Cell, Immunoblastic 1 Leukemia, Hairy Cell 1 Intraocular Lymphoma 1 Immunoproliferative Disorders 1 HTLV-I Infections 1 GATA2 Deficiency 1 Burkitt Lymphoma 1 Anemia, Refractory, with Excess of Blasts 1

Interventions

pembrolizumab 2 fludarabine 2 blinatumomab 2 tislelizumab 1 tisagenlecleucel 1 tetrathiomolybdate 1 relugolix 1 nilotinib 1 isatuximab 1 inavolisib 1 giredestrant 1 fludarabine phosphate 1 enzalutamide 1 abemaciclib 1 Transplantation 1 Neoadjuvant Therapy 1 Monatide (IMS 3015) 1 Melphalan 1 Lenalidomide 1 Immunotherapy 1 Imatinib Mesylate 1 HMPL-013 1 Docetaxel 1 Dexamethasone 1 Dasatinib 1 Cyclophosphamide 1 Chemotherapy, Adjuvant 1 Capecitabine 1 Calcium Dobesilate 1 Biological Assay 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05690984 2026-03-16

EMAT

Medical College of Wisconsin

Phase 2 Active not recruiting

Multiple Myeloma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡